| Literature DB >> 34778969 |
Guangshuo Zhu1, Kazutaka Ueda2,3, Masaki Hashimoto2, Manling Zhang1, Masayuki Sasaki1, Taro Kariya1, Hideyuki Sasaki1, Nina Kaludercic1, Dong-Ik Lee1, Djahida Bedja1, Matthew Gabrielson1, Yuan Yuan1, Nazareno Paolocci1, Robert M Blanton3, Richard H Karas3, Michael E Mendelsohn3,4, Brian O'Rourke1, David A Kass1, Eiki Takimoto1,2.
Abstract
Phosphodiesterase 5 inhibition (PDE5i) activates cGMP-dependent protein kinase (PKG) and ameliorates heart failure; however, its impact on cardiac mitochondrial regulation has not been fully determined. Here, we investigated the role of the mitochondrial regulator peroxisome proliferator-activated receptor γ co-activator-1α (PGC1α) in the PDE5i-conferred cardioprotection, utilizing PGC1α null mice. In PGC1α+/+ hearts exposed to 7 weeks of pressure overload by transverse aortic constriction, chronic treatment with the PDE5 inhibitor sildenafil improved cardiac function and remodeling, with improved mitochondrial respiration and upregulation of PGC1α mRNA in the myocardium. By contrast, PDE5i-elicited benefits were abrogated in PGC1α-/- hearts. In cultured cardiomyocytes, PKG overexpression induced PGC1α, while inhibition of the transcription factor CREB abrogated the PGC1α induction. Together, these results suggest that the PKG-PGC1α axis plays a pivotal role in the therapeutic efficacy of PDE5i in heart failure.Entities:
Keywords: PGC1α; cyclic guanosine monophosphate; heart failure; mitochondria
Mesh:
Substances:
Year: 2021 PMID: 34778969 PMCID: PMC9199229 DOI: 10.1002/1873-3468.14228
Source DB: PubMed Journal: FEBS Lett ISSN: 0014-5793 Impact factor: 3.864